ARTICLE | Finance
Naurex's New Leaf
Why New Leaf led a $65M A round for Naurex spinout Aptinyx
May 16, 2016 7:00 AM UTC
With a clinically validated MOA and a broadly applicable discovery platform, the former Naurex Inc. team convinced new investor New Leaf Venture Partners to lead a tranched $65 million series A round last week for spinout Aptinyx Inc.
Aptinyx houses a platform and preclinical portfolio of oral small molecule NMDA receptor modulators that were not included in last year's acquisition of Naurex by Allergan plc (NYSE:AGN) for $560 million up front, plus undisclosed milestones. ...